Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Current as of November 28, 2023
If you are in the high risk group you will be assigned randomly (like tossing a coin) to receive either AmBisome or fluconazole. If you are in the low risk group, you will not receive any treatment. Both groups will be monitored for IFIs. The study will last for 100 days following your liver transplant.
- Inclusion Criteria:
- You may be eligible for this study if you:
- Have had a liver transplant within 5 days of enrollment and agree to receive tacrolimus.
- Exclusion Criteria:
- You will not be eligible for this study if you:
- Are HIV-positive.
- Have a history of invasive fungal infection.
- Have received antifungal agents within 14 days prior to your liver transplant.
- Are allergic to azoles, amphotericin B, or tacrolimus.
The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Birmingham, Alabama, United States
All reviews come from applied patients